Positive phase 3 libtayo® (cemiplimab) results in advanced cervical cancer presented at esmo virtual plenary

Tarrytown, n.y. and paris, may 12, 2021 /prnewswire/ -- libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy improvements in overall survival were seen in the overall population and both squamous cell carcinoma and adenocarcinoma subgroups additionally, the phase 3 trial found significant differences in patient-reported outcomes favoring libtayo over chemotherapy regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced the presentation of positive results from the phase 3 trial investigating the pd-1 inhibitor libtayo® (cemiplimab) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy.
REGN Ratings Summary
REGN Quant Ranking